It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-shelf’ cancer cell therapies. Gilead’s subsidiary Kite Pharm...
Original Article: Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO